Adage Capital Partners’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Adage Capital Partners’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-450,000	Closed	-$594K	–	968
2023 Q1	$594K	Hold	450,000	–	–	﹤0.01%	815
2022 Q4	$761K	Hold	450,000	–	–	﹤0.01%	851
2022 Q3	$833K	Hold	450,000	–	–	﹤0.01%	897
2022 Q2	$1.38M	Hold	450,000	–	–	﹤0.01%	905
2022 Q1	$3.25M	Hold	450,000	–	–	0.01%	868
2021 Q4	$7.37M	Sell	450,000 -550,000	-55%	-$6.4M	0.01%	771
2021 Q3	$9.95M	Hold	1,000,000	–	–	0.02%	685
2021 Q2	$9.98M	Hold	1,000,000	–	–	0.02%	692
2021 Q1	$9.96M	Buy	+1,000,000	New	+$10.3M	0.02%	676

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Adage Capital Partners's PRDS Position: Q2 2023 in Review

Adage Capital Partners sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2023, closing a stake of 450,000 shares — an estimated $594K sold.

Adage Capital Partners first reported a position in PRDS in Q1 2021 and held it in 9 quarters. The position peaked at $9.98M in Q2 2021. 59 funds tracked by Wall St. Rank hold PRDS as of Q2 2023.

Adage Capital Partners reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Adage Capital Partners sold 450,000 Pardes Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $594K.
Adage Capital Partners first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Adage Capital Partners's Pardes Biosciences, Inc. Common Stock position peaked at $9.98M in Q2 2021.
59 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2023.

Based on Adage Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.